A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis-Reference-Cited by-同舟云学术

A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis

Published:2019-12-25 Issue:1 Volume:84 Page:15-17
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Endo Jin¹,Sano Motoaki¹,Izumiya Yasuhiro²,Tsujita Kenichi³,Nakamura Kazufumi⁴,Tahara Nobuhiro⁵,Kuwahara Koichiro⁶,Inomata Takayuki⁷,Ueda Mitsuharu⁸,Sekijima Yoshiki⁹,Ando Yukio⁸,Tsutsui Hiroyuki¹⁰,Isobe Mitsuaki¹¹,Fukuda Keiichi¹

Affiliation:

1. Department of Cardiology, Keio University School of Medicine

2. Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine

3. Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University

4. Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

5. Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine

6. Department of Cardiovascular Medicine, Shinshu University School of Medicine

7. Department of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital

8. Department of Neurology, Graduate School of Medical Sciences, Kumamoto University

9. Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine

10. Department of Cardiovascular Medicine, Kyusyu University

11. Sakakibara Heart Institute

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/84/1/84_CJ-19-0811/_pdf

Reference4 articles.

1. 1. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012; 109: 9629–9634.

2. 2. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007–1016.

3. 3. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585–2594.

4. 4. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99 mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46: 1076–1084.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis;Journal of Clinical Medicine;2023-07-12

2. Prevalence and Treatment of Arrhythmias in Patients With Transthyretin and Light-Chain Cardiac Amyloidosis;Circulation Reports;2023-07-10

3. Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy;ESC Heart Failure;2023-04-18

4. Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy;Pharmaceutics;2023-04-03

5. Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis;Amyloid;2023-02-16